Natixis Revance Therapeutics, Inc. Transaction History
Natixis
- $16 Billion
- Q4 2024
A detailed history of Natixis transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Natixis holds 10,343 shares of RVNC stock, worth $26,581. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,343Holding current value
$26,581% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding RVNC
# of Institutions
208Shares Held
80.9MCall Options Held
2.26MPut Options Held
5.48M-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Beryl Capital Management LLC Redondo Beach, CA5.94MShares$15.3 Million9.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.63MShares$14.5 Million0.0% of portfolio
-
Oddo Bhf Asset Management Sas Paris, I05.1MShares$13.1 Million0.78% of portfolio
-
Fil LTD Hamilton, D04.2MShares$10.8 Million0.01% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...